Volume | 764,567 |
|
|||||
News | - | ||||||
Day High | 42.09 | Low High |
|||||
Day Low | 41.00 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Ultragenyx Pharmaceutical Inc | RARE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
41.52 | 41.00 | 42.09 | 41.56 | 41.96 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
10,650 | 764,567 | $ 41.43 | $ 31,674,667 | - | 31.52 - 54.98 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:31:35 | 10 | $ 41.26 | USD |
Ultragenyx Pharmaceutical Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.42B | 82.34M | - | 434.25M | -606.64M | -7.37 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ultragenyx Pharmaceutical News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RARE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 42.61 | 46.005 | 41.00 | 42.91 | 1,100,139 | -1.05 | -2.46% |
1 Month | 49.695 | 52.56 | 41.00 | 43.99 | 839,243 | -8.14 | -16.37% |
3 Months | 44.64 | 54.56 | 41.00 | 46.96 | 745,621 | -3.08 | -6.90% |
6 Months | 38.05 | 54.56 | 34.06 | 45.13 | 769,519 | 3.51 | 9.22% |
1 Year | 47.22 | 54.98 | 31.52 | 42.71 | 760,061 | -5.66 | -11.99% |
3 Years | 112.42 | 115.25 | 31.52 | 53.72 | 639,935 | -70.86 | -63.03% |
5 Years | 62.23 | 179.647 | 31.52 | 61.61 | 575,210 | -20.67 | -33.22% |
Ultragenyx Pharmaceutical Description
Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. |